Key facts
- This page summarizes James Patrick Tursi's Form 4 filing for AGILE THERAPEUTICS INC.
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 10 Jun 2022, 16:45.
James Patrick Tursi - 09 Jun 2022 Form 4 Insider Report for AGILE THERAPEUTICS INC
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 09 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 10 Jun 2022, 16:45:55 UTC
- Prior SEC filing
- 24 Feb 2022
- Next SEC filing
- 17 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Geoffrey P. Gilmore, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James Patrick Tursi filed Form 4 for AGILE THERAPEUTICS INC on 10 Jun 2022.
Change
- Previous filing in this sequence was filed on 24 Feb 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AGRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +670
- Change %
- +48%
- Price
- $0.000000
- Shares after
- 2,066
- Date
- 09 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGRX
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +807
- Change %
- Price
- $0.000000
- Shares after
- 807
- Date
- 09 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 807
- Exercise price
- $1.22
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares represent restricted stock units that were granted on June 9, 2022, which will vest and be settled in common stock on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.
Footnote F2
On April 26, 2022, the Issuer completed a one-for-forty reverse stock split of the Issuer's common stock. This amount has been adjusted to give effect to this reverse stock split.
Footnote F3
This option was granted on June 9, 2022 and vests in full on June 9, 2023, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date and provided that the Reporting Person attends at least 75% of the board meetings held during the year of board service.